Clinical trial · Observational
Modeling of the Response to Hypofractionated Stereotactic Pulmonary Irradiation
Multiscale Modeling / Simulation of the Response to Pulmonary Stereotactic Hypofractionated Irradiation
NCT03175861CI-TRIAL-00035382MUMOFRATunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Identify 18-Fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) parameters predictive of tumor response and local control
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oncology | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic radiotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Kinetics of PET-CT parameters : standardized uptake value (SUV) max
- timeFrame
- 2 years
- description
- SUV max will be measured before and after stereotactic irradiation.
- measure
- Tumor metabolic response
- timeFrame
- 2 years
- description
- Tumor metabolic response, as assessed on 18F-FDG PET-CT at 6 months of end of radiotherapy
- measure
- Local control
- timeFrame
- 2 years
- description
- Local control defined by the absence of progression in the irradiated area
- measure
- Kinetics of PET-CT parameters : metabolic tumor volume
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age\> 18 years * Performance Index WHO (World Health Organization) ≤ 2 * Bronchopulmonary carcinoma not in small cells proved histologically or cytologically (epidermoid, adenocarcinoma, or large cell carcinoma). * Tumor classified T1 - T2 (Tumor=1-2) N0 (Node=0) M0 (Metastasis=0) and diameter ≤ 5 cm or Tumor classified T3 (≤5cm) N0M0 of the chest wall * Tumor located more than 2 cm from the trachea and bronchus stem and more than 1.5 cm from the organs at risk * Medically inoperable or refusing surgery * Indication of stereotactic radiotherapy validated in multidisciplinary consultation meeting * Formulation of consent Exclusion Criteria: * Age \<18 years. * History of pulmonary irradiation * Pulmonary surgery of the tumor * Different histology of non-small cell carcinoma * Patient with a T2 or T3\> 5 cm tumor or patients with a T3 tumor invading a structure other than the chest wall * Patient with a tumor within 2 cm of the trachea and bronchus stem and within 1.5 cm of the organs at risk in the proximal area of the no fly zone (defined as a volume Located 2 cm in all directions of the proximal bronchial tree - Pulmonary metastases * Declared pregnancy, breast-feeding * Refusal to use effective contraception * Against indication to the realization of the PET to the 18FDG (18-fluorodeoxyglucose)(uncontrolled diabetes) * Refusal or inability to consent to participate in the study. * Estimated life expectancy \<2 months in the absence of treatment * Other invasive tumors diagnosed in the previous 2 years, with the exception of non-melanocytic cutaneous carcinomas.
References
Publications (0)
Data not yet available
No reference posted for this study.